GM-CSF-armed, replication-competent viruses for cancer

Cytokine and Growth Factor Reviews

Volumn 21, Issue 2-3, 2010, Pages 149-151

  Burke, James M ^a  

^a BILLINGS CLINIC   (United States)

Author keywords

Adenovirus; Cancer; Gene therapy; GM CSF; Herpes; Immunotherapy; Replication competent; Tumor vaccine; Vaccinia

Indexed keywords

BCG VACCINE; CG 0070; E1A PROTEIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; JX 594; ONCOLYTIC HERPES VIRUS; ONCOLYTIC VIRUS; TRANSCRIPTION FACTOR E2F; TUMOR VACCINE; UNCLASSIFIED DRUG; CANCER VACCINE;

BLADDER CANCER; CARCINOMA IN SITU; CHILL; CLINICAL TRIAL; CYSTALGIA; DRUG FEVER; DYSURIA; FLU LIKE SYNDROME; HUMAN; HYPERBILIRUBINEMIA; IMMUNOSTIMULATION; LIVER CANCER; LIVER CELL CARCINOMA; LIVER METASTASIS; MELANOMA; MOLECULARLY TARGETED THERAPY; NAUSEA; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; URINARY FREQUENCY; VIRUS GENOME; VIRUS REPLICATION; CLINICAL TRIAL (TOPIC); GENE THERAPY; GENE VECTOR; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS; PROCEDURES; VIRUS;

CANCER VACCINES; CLINICAL TRIALS AS TOPIC; GENE THERAPY; GENETIC VECTORS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOTHERAPY; NEOPLASMS; VIRUSES; GENETIC THERAPY;

ADENOVIRIDAE; HERPES; REPLICATION COMPETENT VIRUSES;

EID: 77953537985     PISSN: 13596101     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2010.02.002     Document Type: Review

References (9)

1. Atkins M.B. Cytokine-based therapy and biochemotherapy for advanced melanoma. Clin Cancer Res 2006, 12(April (7 Pt 2)):2353s-2358s.
2. Sondak V.K., Wolfe J.A. Adjuvant therapy for melanoma. Curr Opin Oncol 1997, 9(March (2)):189-204.
3. Higano C.S., Schellhammer P.F., Small E.J., Burch P.A., Nemunaitis J., Yuh L., et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009, 115(August (16)):3670-3679.
4. Senzer N.N., Kaufman H.L., Amatruda T., Nemunaitis M., Reid T., Daniels G., et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol 2009, 27(December (34)):5763-5771.
5. Mastrangelo M.J., Maguire H.C., Lattime E.C. Intralesional vaccinia/GM-CSF recombinant virus in the treatment of metastatic melanoma. Adv Exp Med Biol 2000, 465:391-400.
6. Park B.H., Hwang T., Liu T.C., Sze D.Y., Kim J.S., Kwon H.C., et al. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol 2008, 9(June (6)):533-542. [Epub 2008 May 19].
7. McKiernan J., Lamm D., Meng M., Nemunaitis J., Arseneau J., Stephenson J., et al. Abstract: phase 1 study of single and multi-dose administration of intravesical CG0070 in patients with non-muscle invasive bladder cancer (NMIBC). Fifth International Meeting on Replicating Oncolytic Virus Therapeutics-Bannf 2009.
8. Dranoff G., Jaffee E., Lazenby A., Golumbek P., Levitsky H., Brose K., et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993, 90(April (8)):3539-3543.
9. Mittendorf E.A., Sharma P. Mechanisms of T-cell inhibition: implications for cancer immunotherapy. Expert Rev Vaccines 2010, 9(January (1)):89-105.